C4 Therapeutics (CCCC) Competitors $1.52 +0.04 (+2.70%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$1.50 -0.02 (-1.38%) As of 07/7/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CCCC vs. FULC, RVNC, ITOS, ETON, RZLT, CYRX, ERAS, VIGL, CKPT, and TECXShould you be buying C4 Therapeutics stock or one of its competitors? The main competitors of C4 Therapeutics include Fulcrum Therapeutics (FULC), Revance Therapeutics (RVNC), iTeos Therapeutics (ITOS), Eton Pharmaceuticals (ETON), Rezolute (RZLT), CryoPort (CYRX), Erasca (ERAS), Vigil Neuroscience (VIGL), Checkpoint Therapeutics (CKPT), and Tectonic Therapeutic (TECX). These companies are all part of the "pharmaceutical products" industry. C4 Therapeutics vs. Its Competitors Fulcrum Therapeutics Revance Therapeutics iTeos Therapeutics Eton Pharmaceuticals Rezolute CryoPort Erasca Vigil Neuroscience Checkpoint Therapeutics Tectonic Therapeutic C4 Therapeutics (NASDAQ:CCCC) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership and profitability. Do institutionals & insiders have more ownership in CCCC or FULC? 78.8% of C4 Therapeutics shares are held by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are held by institutional investors. 8.7% of C4 Therapeutics shares are held by insiders. Comparatively, 7.0% of Fulcrum Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has better earnings & valuation, CCCC or FULC? Fulcrum Therapeutics has higher revenue and earnings than C4 Therapeutics. Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioC4 Therapeutics$35.58M3.03-$105.32M-$1.47-1.03Fulcrum Therapeutics$80M4.74-$9.73M-$0.07-100.29 Does the media refer more to CCCC or FULC? In the previous week, Fulcrum Therapeutics had 2 more articles in the media than C4 Therapeutics. MarketBeat recorded 2 mentions for Fulcrum Therapeutics and 0 mentions for C4 Therapeutics. C4 Therapeutics' average media sentiment score of 0.00 equaled Fulcrum Therapeutics'average media sentiment score. Company Overall Sentiment C4 Therapeutics Neutral Fulcrum Therapeutics Neutral Which has more risk and volatility, CCCC or FULC? C4 Therapeutics has a beta of 2.94, suggesting that its share price is 194% more volatile than the S&P 500. Comparatively, Fulcrum Therapeutics has a beta of 2.37, suggesting that its share price is 137% more volatile than the S&P 500. Do analysts rate CCCC or FULC? C4 Therapeutics currently has a consensus target price of $12.00, suggesting a potential upside of 689.47%. Fulcrum Therapeutics has a consensus target price of $6.29, suggesting a potential downside of 10.46%. Given C4 Therapeutics' higher probable upside, analysts clearly believe C4 Therapeutics is more favorable than Fulcrum Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score C4 Therapeutics 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50Fulcrum Therapeutics 1 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.50 Is CCCC or FULC more profitable? Fulcrum Therapeutics has a net margin of 0.00% compared to C4 Therapeutics' net margin of -259.60%. Fulcrum Therapeutics' return on equity of -0.20% beat C4 Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets C4 Therapeutics-259.60% -45.86% -28.96% Fulcrum Therapeutics N/A -0.20%-0.19% SummaryFulcrum Therapeutics beats C4 Therapeutics on 11 of the 15 factors compared between the two stocks. Get C4 Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CCCC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CCCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CCCC vs. The Competition Export to ExcelMetricC4 TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$105.09M$2.91B$5.52B$9.02BDividend YieldN/A2.44%5.24%4.08%P/E Ratio-1.0320.3027.1920.04Price / Sales3.03250.25413.81108.84Price / CashN/A41.7026.2128.59Price / Book0.507.397.925.55Net Income-$105.32M-$55.04M$3.17B$248.49M7 Day Performance0.66%2.51%1.78%4.87%1 Month Performance-12.14%-0.21%1.26%6.63%1 Year Performance-65.69%3.41%33.30%20.38% C4 Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CCCCC4 Therapeutics1.4354 of 5 stars$1.52+2.7%$12.00+689.5%-66.4%$105.09M$35.58M-1.03150FULCFulcrum Therapeutics0.2042 of 5 stars$6.88-3.1%$6.29-8.6%+13.4%$383.25M$80M-98.27100RVNCRevance Therapeutics2.7281 of 5 stars$3.65flat$8.45+131.5%N/A$381.02M$234.04M-1.89500ITOSiTeos Therapeutics3.1285 of 5 stars$9.97+0.2%$15.86+59.0%-28.1%$380.82M$35M-3.2890ETONEton Pharmaceuticals2.7064 of 5 stars$14.25+1.7%$29.67+108.2%+333.4%$375.72M$48.33M-79.1720RZLTRezolute2.2278 of 5 stars$4.46+2.5%$11.83+165.3%+20.6%$372.01MN/A-3.8840High Trading VolumeCYRXCryoPort2.9255 of 5 stars$7.46+0.7%$11.00+47.5%+12.5%$371.52M$228.38M-3.191,186Analyst ForecastGap DownERASErasca3.0172 of 5 stars$1.27-3.1%$4.57+260.0%-34.6%$371.11MN/A0.00120VIGLVigil Neuroscience3.3145 of 5 stars$7.95flat$10.80+35.8%+98.3%$371.04MN/A0.0040CKPTCheckpoint Therapeutics0.4161 of 5 stars$4.26flat$4.33+1.7%N/A$370.71M$41K-2.3210TECXTectonic Therapeutic3.0168 of 5 stars$19.87+0.4%$83.60+320.7%+31.9%$369.72MN/A0.00120Analyst Upgrade Related Companies and Tools Related Companies Fulcrum Therapeutics Competitors Revance Therapeutics Competitors iTeos Therapeutics Competitors Eton Pharmaceuticals Competitors Rezolute Competitors CryoPort Competitors Erasca Competitors Vigil Neuroscience Competitors Checkpoint Therapeutics Competitors Tectonic Therapeutic Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CCCC) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredInstant Cash (in 4 clicks)Since 1973, Wall Street has quietly used a strange little pricing quirk to cash flow billions. Now, for the...Awesomely, LLC | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding C4 Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share C4 Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CCCC Stock Alerts